ArticleCureus2026
Achieving Rapid Remission With Guselkumab in a Moderately Active Ulcerative Colitis Patient With High Infectious Risk and Inadequate Response to Advanced Therapy: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) with prior inadequate response to advanced therapy (AT-IR) that requires hospitalization is particularly challenging to manage, especially in cases where a high risk of infection limits the use of immunosuppressive agents. A 32-year-old male patient with pancolitis-type UC was refractory to glucocorticosteroids, infliximab, and tacrolimus. His clinical course was complicated by septic shock and invasive candidiasis. Antifungal therapy limited the use of upadacitinib due to drug-drug interactions. After achieving infection control, intravenous guselkumab (200 mg) was initiated. The patient's stool frequency normalized, and hematochezia resolved within two weeks. The patient achieved clinical remission, and he was then discharged. In conclusion, guselkumab achieved clinical remission in a patient with active UC with AT-IR, in whom the risk of infection was high and other advanced therapies were restricted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.